The market for psychedelic drugs to treat mental health conditions gets a big buy signal

AI Summary

Eli Lilly has acquired psychedelic drug maker AtaiBeckley, signaling a significant move in the mental health drug market. This acquisition reflects Big Pharma's growing interest in psychedelic treatments for mental health conditions.

Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.